위장관기질종양에서 DOG1 발현의 진단적 유용성
Usefulness of DOG1 Expression in the Diagnosis of Gastrointestinal Stromal Tumors
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Background : Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the gastrointestinal tract. Expression of KIT protein (CD117) is an important diagnostic criterion of GIST. However, about 5% of GISTs are CD117 negative. Discovered on GIST 1 (DOG1) was introduced recently as a promising marker for GIST. We tested this new antibody in 105 GISTs tissue specimens, including 6 cases of metastatic GISTs, to determine the usefulness of DOG1 expression in the diagnosis of GISTs. Methods : We performed immunohistochemical (IHC) staining for DOG1 and CD117 on tissue microarrays that included 70 gastric GISTs, 29 small intestinal GISTs, 6 metastatic GISTs, 14 gastric leiomyomas and 16 gastric schwannomas. Results : DOG1 was positive in 98.1% (103/105) of GISTs and CD117 was positive in 97.1% (102/105) of GISTs. Only 1 case was negative for both markers. Two (66.7%) out of 3 GISTs tested CD117 negative were tested DOG1 positive. All leiomyomas and schwannomas were negative for both DOG1 and CD117. Conclusions : DOG1 was highly expressed in GIST including CD117 negative cases. Adding DOG1 testing to the IHC panel for diagnosing GIST will help to identify GIST patients who are CD117 negative but may otherwise benefit from targeted therapy.
Abstract
Background : Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the gastrointestinal tract. Expression of KIT protein (CD117) is an important diagnostic criterion of GIST. However, about 5% of GISTs are CD117 negative. Discovered on GIST 1 (DOG1) was introduced recently as a promising marker for GIST. We tested this new antibody in 105 GISTs tissue specimens, including 6 cases of metastatic GISTs, to determine the usefulness of DOG1 expression in the diagnosis of GISTs. Methods : We performed immunohistochemical (IHC) staining for DOG1 and CD117 on tissue microarrays that included 70 gastric GISTs, 29 small intestinal GISTs, 6 metastatic GISTs, 14 gastric leiomyomas and 16 gastric schwannomas. Results : DOG1 was positive in 98.1% (103/105) of GISTs and CD117 was positive in 97.1% (102/105) of GISTs. Only 1 case was negative for both markers. Two (66.7%) out of 3 GISTs tested CD117 negative were tested DOG1 positive. All leiomyomas and schwannomas were negative for both DOG1 and CD117. Conclusions : DOG1 was highly expressed in GIST including CD117 negative cases. Adding DOG1 testing to the IHC panel for diagnosing GIST will help to identify GIST patients who are CD117 negative but may otherwise benefit from targeted therapy.
참고문헌 (25)
- Hirota S, "Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors", Science, 279, pp.577~580 (1998)
- Rubin BP, "KIT activation is a ubiquitous feature of gastrointestinal stromal tumors", Cancer Res, 61, pp.8118~8121 (2001)
- Heinrich MC, "PDGFRA activating mutations in gastrointestinal stromal tumors", Science, 299, pp.708~710 (2003)
- Hornick JL, "The role of KIT in the management of patients with gastrointestinal stromal tumors", Hum Pathol, 38, pp.679~687 (2007)
- Miettinen M, "Gastrointestinal stromal tumors:review on morphology,molecular pathology,prognosis,and differential diagnosis", Arch Pathol Lab Med, 130, pp.1466~1478 (2006)
- Medeiros F, "KIT-negative gastrointestinal stromal tumors:proof of concept and therapeutic implications", Am J Surg Pathol, 28, pp.889~894 (2004)
- Corless CL, "PDGFRA mutations in gastrointestinal stromal tumors:frequency,spectrum and in vitro sensitivity to imatinib", J Clin Oncol, 23, pp.5357~5364 (2005)
- Hirota S, "Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors", Gastroenterology, 125, pp.660~667 (2003)
- Pauls K, "PDGFRalpha-and c-kit-mutated gastrointestinal stromal tumours(GISTs)are characterized by distinctive histological and immunohistochemical features", Histopathology, 46, pp.166~175 (2005)
- van Oosterom AT, "Safety and efficacy of imatinib(STI571)in metastatic gastrointestinal stromal tumours:a phase I study", Lancet, 358, pp.1421~1423 (2001)
- Joensuu H, "Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor", N Engl J Med, 344, pp.1052~1056 (2001)
- Demetri GD, "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors", N Engl J Med, 347, pp.472~480 (2002)
- Duensing A, "Protein Kinase C theta(PKCtheta)expression and constitutive activation in gastrointestinal stromal tumors(GISTs)", Cancer Res, 64, pp.5127~5131 (2004)
- Lee HE, "Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining", J Clin Pathol, 61, pp.722~729 (2008)
- Blay P, "Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias", Clin Cancer Res, 10, pp.4089~4095 (2004)
- Kim KM, "PKCtheta expression in gastrointestinal stromal tumor", Mod Pathol, 19, pp.1480~1486 (2006)
- West RB, "The novel marker,DOG1,is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status", Am J Pathol, 165, pp.107~113 (2004)
- Espinosa I, "A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors", Am J Surg Pathol, 32, pp.210~218 (2008)
- Liegl B, "Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors,including unusual subtypes", Am J Surg Pathol, 33, pp.437~446 (2009)
- Miettinen M, "DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors:a study of 1840 cases", Am J Surg Pathol, 33, pp.1401~1408 (2009)
- Miwa S, "Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors(GISTs)", J Gastroenterol, 43, pp.531~537 (2008)
- 석상희, "위와 소장에서 발생한 위장관기질종양의 예후 비교분석 - 단일기관 126예를 대상으로 한 후향적 연구 -", The Korean Journal of Pathology, 42(6), pp.335~343 (2008), 대한병리학회
- Fletcher CD, "Diagnosis of gastrointestinal stromal tumors:a consensus approach", Hum Pathol, 33, pp.459~465 (2002)
- Kyoung-Mee Kim, "Gastrointestinal Stromal Tumors in Koreans:It's Incidence and the Clinical,Pathologic and Immunohistochemical Findings", Journal of Korean Medical Science, 20(6), pp.977~984 (2005), 대한의학회
- 강동욱, "위장관 간질종양에서 c-kit유전자 돌연변이 및 면역조직화학적 발현", The Korean Journal of Pathology, 37(4), pp.246~254 (2003), 대한병리학회